Table 4.
Ongoing non-invasive non-pharmacological clinical trials registered at theWorld Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington’s disease (HD)
| Registration ID | Trial name | Intervention | Mechanism of Action | Population | Comparison | Main outcome | Study design | Esimated Enrolment | Sponsor | Location |
| ACTRN126180 01717246 | – | Multidisciplinary therapy program | Exercise, cognitive training, lifestyle guidance and social activities | PremanifestHD | Standard of care | Feasability and safety | Clustered, non-randomized, open label, parallel trial | 40 | Edith Cowan University, Deakin University and Lotterywest | Australia (two centres) |
| NCT03417583 | – | Neuropsychiatric treatment protocol | Multidisciplinary intervention | HD with neuropsychiatric symptoms | Standard of care | Change in quality of life at 18 months | Non-randomized, assessor-blinded, parallel trial | 100 | Vanderbilt University Medical Center and Teva Pharmaceuticals USA | USA (single centre) |
| CTRI/2018/01/011359 | – | Repetitive transcranial magnetic stimulation | Transcranial magnetic stimulation | Early to moderate HD and PD | Sham stimulation | Efficacy at 5 days | Randomized, single-blind, placebo-controlled, parallel trial | 40 | Vinay Goyal | India (single centre) |
| NCT03344601 | PACE-HD | Supported structured aerobic exercise training program | Physiotherapy | HD | Activity as usual | Data completeness, recruitment, retention, safety, adherence, fidelity and acceptability at 12 months | Nested open-label, randomized controlled parallel trial | 120 | Cardiff University and CHDI Foundation, Inc | Germany, Spain and USA (multi centre) |
| ACTRN126170 01269325 | – | Swallowing skill training | Speech and language therapy | HD and ALS | None | Swallowing function and quality of life at 2 weeks | Single group, open-label trial | 54 | University of Canterbury | New Zealand (single centre) |
| NCT02216474 | – | tDCS | Transcranial magnetic stimulation | HD or Tourette Syndrome | Sham stimulation | Efficacy at 2 weeks | Randomized, double-blind, placebo-controlled, cross-over trial | 100 | Birmingham and Solihull Mental Health NHS Foundation Trust, University of Birmingham | UK (single centre) |
AD, Alzheimer’s disease; ALS, Amyotrophic Lateral Sclerosis; ET, Essential Tremor; HT, Holmes Tremor; MS, Multiple Sclerosis; PD, Parkinson’s disease; TD, Tardive dyskinesia.